marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
AcelRx Pharmaceuticals Balance Sheet 2011-2024 | ACRX
Annual Balance Sheet AcelRx Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -6.59 M | -5.4 M | 10.5 M | -76 M | -33.8 M | -58.8 M | -87 M | -35.1 M | -74 M | -32 M | 11.3 M |
Long Term Debt |
- | - | 5.01 M | 13.1 M | 20.5 M | 3.38 M | 11.4 M | 18.6 M | 16.4 M | 18 M | 14.4 M | 8.53 M | 15.3 M |
Long Term Debt Current |
- | 5.36 M | 1.07 M | 1.12 M | 970 K | 8.61 M | 7.73 M | 2.91 M | 4.54 M | 6.86 M | - | 7.44 M | 3.8 M |
Total Non Current Liabilities |
- | - | - | 104 M | 119 M | 100 M | 98.4 M | 95.1 M | 81.9 M | 26.1 M | 30 M | 16.3 M | 15.5 M |
Total Current Liabilities |
4.51 M | 13.8 M | 18.5 M | 17.6 M | 13.6 M | 15.9 M | 13.7 M | 10.2 M | 12.8 M | 13.7 M | 6.87 M | 14.3 M | 7.84 M |
Total Liabilities |
6.29 M | 25.7 M | 114 M | 122 M | 133 M | 116 M | 112 M | 105 M | 94.7 M | 39.8 M | 36.9 M | 30.7 M | 23.4 M |
Deferred Revenue |
- | - | - | 49 K | 411 K | 315 K | 362 K | 362 K | 2.6 M | 787 K | 623 K | - | - |
Retained Earnings |
-444 M | -426 M | -474 M | -438 M | -398 M | -345 M | -298 M | -246 M | -203 M | -179 M | -145 M | -122 M | -88.7 M |
Total Assets |
20.4 M | 47.5 M | 77.9 M | 66.3 M | 91.4 M | 121 M | 75.6 M | 100 M | 128 M | 86.4 M | 110 M | 64.5 M | 40.8 M |
Cash and Cash Equivalents |
5.72 M | 15.3 M | 7.66 M | 27.3 M | 14.7 M | 88 M | 52.9 M | 80.3 M | 108 M | 60 M | 88.4 M | 47.9 M | 7.79 M |
Book Value |
14.1 M | 21.8 M | -35.9 M | -55.8 M | -41.4 M | 4.25 M | -36.5 M | -5.34 M | 33.1 M | 46.7 M | 73.2 M | 33.8 M | 17.5 M |
Total Shareholders Equity |
14.1 M | 21.8 M | -35.9 M | -55.8 M | -41.4 M | 4.25 M | -36.5 M | -5.34 M | 33.1 M | 46.7 M | 73.2 M | 33.8 M | 17.5 M |
All numbers in USD currency
Quarterly Balance Sheet AcelRx Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | 3.04 M | 5.01 M | 6.95 M | 9.37 M | 11.3 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 3.38 M | 3.38 M | 3.38 M | 3.38 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 18 M | 18 M | 18 M | 18 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 8.53 M | 8.53 M | 8.53 M | 8.53 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.4 M | 12.1 M | 12.4 M | 6.29 M | 4.95 M | 7.31 M | 12 M | 25.7 M | 20.8 M | 23 M | 110 M | 114 M | 115 M | 116 M | 115 M | 122 M | 122 M | 122 M | 122 M | 133 M | 133 M | 133 M | 133 M | 116 M | 116 M | 116 M | 116 M | 112 M | 112 M | 112 M | 112 M | 105 M | 105 M | 105 M | 105 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M | 30.7 M | 30.7 M | 30.7 M | 30.7 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49 K | 196 K | 300 K | 300 K | 300 K | 411 K | 411 K | 411 K | 315 K | 326 K | 338 K | 350 K | 362 K | 362 K | 362 K | 362 K | 362 K | 362 K | 362 K | 362 K | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 787 K | 787 K | 787 K | 787 K | 623 K | 623 K | 623 K | 623 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-455 M | -452 M | -448 M | -444 M | -440 M | -438 M | -434 M | -426 M | -418 M | -412 M | -482 M | -474 M | -466 M | -457 M | -447 M | -438 M | -438 M | -438 M | -438 M | -398 M | -398 M | -398 M | -398 M | -345 M | -345 M | -345 M | -345 M | -298 M | -298 M | -298 M | -298 M | -246 M | -246 M | -246 M | -246 M | -203 M | -203 M | -203 M | -203 M | -179 M | -179 M | -179 M | -179 M | -145 M | -145 M | -145 M | -145 M | -122 M | -122 M | -122 M | -122 M | -88.7 M | -88.7 M | -88.7 M | -88.7 M |
Total Assets |
21 M | 24.9 M | 28.8 M | 20.4 M | 23.3 M | 17.7 M | 26.3 M | 47.5 M | 48.3 M | 56.1 M | 72 M | 77.9 M | 72.3 M | 79.6 M | 87.3 M | 66.3 M | 66.3 M | 66.3 M | 66.3 M | 91.4 M | 91.4 M | 91.4 M | 91.4 M | 121 M | 121 M | 121 M | 121 M | 75.6 M | 75.6 M | 75.6 M | 75.6 M | 100 M | 100 M | 100 M | 100 M | 128 M | 128 M | 128 M | 128 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 110 M | 110 M | 110 M | 110 M | 64.5 M | 64.5 M | 64.5 M | 64.5 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M |
Cash and Cash Equivalents |
11.1 M | 13.4 M | 12.1 M | 5.72 M | 13.4 M | 7.41 M | 13.4 M | 15.3 M | 12.7 M | 15.2 M | 21.8 M | 7.66 M | 8.27 M | 21.3 M | 34.4 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 88 M | 88 M | 88 M | 88 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 80.3 M | 80.3 M | 80.3 M | 80.3 M | 108 M | 108 M | 108 M | 108 M | 60 M | 60 M | 60 M | 60 M | 88.4 M | 88.4 M | 88.4 M | 88.4 M | 47.9 M | 47.9 M | 47.9 M | 47.9 M | 7.79 M | 7.79 M | 7.79 M | 7.79 M |
Book Value |
9.64 M | 12.7 M | 16.3 M | 14.1 M | 18.3 M | 10.4 M | 14.2 M | 21.8 M | 27.5 M | 33.1 M | -38.3 M | -35.9 M | -43 M | -36 M | -27.3 M | -55.8 M | -55.8 M | -55.8 M | -55.8 M | -41.4 M | -41.4 M | -41.4 M | -41.4 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | -36.5 M | -36.5 M | -36.5 M | -36.5 M | -5.34 M | -5.34 M | -5.34 M | -5.34 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M |
Total Shareholders Equity |
9.64 M | 12.7 M | 16.3 M | 14.1 M | 18.3 M | 10.4 M | 14.2 M | 21.8 M | 27.2 M | 33.1 M | -38.3 M | -35.9 M | -43 M | -36 M | -27.3 M | -55.8 M | -55.8 M | -55.8 M | -55.8 M | -41.4 M | -41.4 M | -41.4 M | -41.4 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | -36.5 M | -36.5 M | -36.5 M | -36.5 M | -5.34 M | -5.34 M | -5.34 M | -5.34 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M |
All numbers in USD currency